   Signature Page Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Protocol Identifying Number: TP-0011713 IDE Number: G220181 IDE Sponsor: Tandem Diabetes Care, Inc. Version Number: v 3.0 20 SEP 2022 Medical Monitor and Protocol Chair Name, degree Title Jordan Pinsker, MD Vice President & Medical Director, Tandem Diabetes Care Signature/Date Sponsor Representative Name, degree Title Ravid Sasson-Katchalski, PhD Director, Clinical Affairs, Tandem Diabetes Care Signature/Date 
B1Ravid KatchalskiDigitally signed by Ravid Katchalski Date: 2022.09.26 15:03:32 -07'00'Jordan PinskerDigitally signed by Jordan Pinsker Date: 2022.09.26 15:22:15 -07'00'

 
  Protocol Revision History Version Number Amendment Date Brief Description of Changes 1.0 16 MAY 2022 Initial Version Submitted to FDA 2.0 27 JUL 2022 Initial Version Approved by FDA 3.0 20 SEP 2022 Updated for consistency between sections and figures: • Study schematic figure updated to note Sleep Activity is required • Synopsis and Section 3.4 updated to add day 1 contact to match tables • Section 2.3.1 and 3.3: Clarified pregnancy test is for females “of childbearing potential” • Section 3.3: Clarified target is 112.5 mg/dL to be consistent with rest of protocol • Section 3.:4 Corrected visit numbers 10 and 14, and updated reference to section 3.4.1 Section 6.24: Clarified when a hyperglycemia/ketotic event qualifies as an AE, or as a SAE, an adverse event form should be completed.   
B2

 
   TABLE OF CONTENTS SITE PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE .............................................................. 8 CHAPTER 1: BACKGROUND INFORMATION .............................................................................................. 15 1.1 Introduction ........................................................................................................................................ 15 1.1.1 Disease Background ..................................................................................................................... 15 1.1.2 Tandem X2 Insulin Pump with Control-IQ Technology ............................................................. 15 1.2 Rationale ............................................................................................................................................. 15 1.3 Potential Risks and Benefits ............................................................................................................... 15 1.3.1 Known Potential Risks ................................................................................................................. 16 1.3.1.1 Blood Draw .......................................................................................................................... 16 1.3.1.2 CGM and Pump Catheter Risks ........................................................................................... 16 1.3.1.3 Hypoglycemia ...................................................................................................................... 16 1.3.1.4 Risk of Hyperglycemia ........................................................................................................ 16 1.3.1.5 Risk of Device Reuse ........................................................................................................... 16 1.3.1.6 Potential Risks of the CLC System ..................................................................................... 16 1.3.1.7 Other Risks .......................................................................................................................... 17 1.3.2 Benefits ........................................................................................................................................ 17 1.3.3 Risk Assessment ........................................................................................................................... 17 1.4 General Considerations ...................................................................................................................... 17 CHAPTER 2: STUDY ENROLLMENT AND LEAD-IN PERIOD ...................................................................... 18 2.1 Participant Recruitment and Enrollment ............................................................................................ 18 2.1.1 Informed Consent and Authorization Procedures ........................................................................ 18 2.2 Participant Eligibility Criteria ............................................................................................................ 19 2.2.1 Inclusion Criteria .......................................................................................................................... 19 2.2.2 Exclusion Criteria ......................................................................................................................... 19 2.3 Visit 1: Screening Visit ...................................................................................................................... 20 2.3.1 Data Collection and Testing ......................................................................................................... 20 2.4 Screen Failures ................................................................................................................................... 21 CHAPTER 3: DEVICE TRAINING AND STUDY VISITS ................................................................................ 22 3.1 Visit 2: Control-IQ 1.5 Training Visit ................................................................................................ 22 3.1.1 Training on System Use ............................................................................................................... 22 3.1.2 Training on Management of Hypoglycemia ................................................................................ 23 3.1.3 Training on Management of Hyperglycemia ............................................................................... 23 3.2 Visits 3, 4 and 5: Control-IQ 1.5 follow up contacts ......................................................................... 24 B3

 
  3.3 Visit 6: Control-IQ 2.0 Training Visit ................................................................................................ 24 3.4 Study Contacts in the Treatment Period with Control-IQ 2.0 Technology ........................................ 25 3.4.1 Procedures at all Study Visits ...................................................................................................... 26 3.5 Unscheduled Visits ............................................................................................................................. 27 3.6 Late Bolus Meal Challenges............................................................................................................... 27 3.7 Adjustments in Insulin Pump Settings ............................................................................................... 27 3.8 Early Discontinuation of Study Device .............................................................................................. 27 3.9 Remote Monitoring ............................................................................................................................ 27 CHAPTER 4: STUDY DEVICES AND DRUGS ................................................................................................ 28 4.1 Study Devices ..................................................................................................................................... 28 4.1.1 Insulin Pump ................................................................................................................................ 28 4.1.2 Continuous Glucose Monitoring .................................................................................................. 28 4.1.3 Blood Glucose Meter ................................................................................................................... 28 4.1.4 Ketone Meter ................................................................................................................................ 28 4.2 Study Device and Drug Accountability Procedures ........................................................................... 28 4.3 Participant Access to Study Device at Study Closure ........................................................................ 28 CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES .................................................................. 29 5.1 General Challenge Guidelines ............................................................................................................ 29 5.1.1 Late Bolus Meal Challenges ........................................................................................................ 29 5.2 Laboratory Testing ............................................................................................................................. 30 5.2.1 HbA1c .......................................................................................................................................... 30 5.2.2 Urine Pregnancy ........................................................................................................................... 30 5.2.3 Patient Reported Outcomes .......................................................................................................... 30 CHAPTER 6: UNANTICIPATED PROBLEM, ADVERSE EVENT, AND DEVICE ISSUE REPORTING ............. 32 6.1 Unanticipated Problems ..................................................................................................................... 32 6.2 Adverse Events ................................................................................................................................... 32 6.2.1 Definitions .................................................................................................................................... 32 6.2.2 Reportable Adverse Events .......................................................................................................... 33 6.2.3 Hypoglycemic Events .................................................................................................................. 34 6.2.4 Hyperglycemic/Ketotic Events .................................................................................................... 34 6.2.5 Relationship of Adverse Event to Study Investigational Device ................................................. 35 6.2.6 Severity (Intensity) of Adverse Events ........................................................................................ 35 6.2.7 Expectedness ................................................................................................................................ 36 6.2.8 Coding of Adverse Events ........................................................................................................... 36 6.2.9 Outcome of Adverse Events ......................................................................................................... 36 B4

 
    6.3 Reportable Device Issues ................................................................................................................... 36 6.4 Timing of Event Reporting................................................................................................................. 37 6.5 Safety Oversight ................................................................................................................................. 37 6.6 Stopping Criteria ................................................................................................................................ 38 6.6.1 Participant Discontinuation of Study Device ............................................................................... 38 6.6.2 Criteria for Suspending or Stopping Overall Study ..................................................................... 38 CHAPTER 7: MISCELLANEOUS CONSIDERATIONS ................................................................................... 39 7.1 Drugs Used as Part of the Protocol .................................................................................................... 39 7.2 Collection of Medical Conditions and Medications ........................................................................... 39 7.3 Prohibited Medications, Devices, Treatments, and Procedures ......................................................... 39 7.4 Rescue Medications, Treatments, and Procedures ............................................................................. 39 7.5 Pregnancy Reporting .......................................................................................................................... 39 7.6 Participant Compensation................................................................................................................... 39 7.7 Participant Withdrawal ....................................................................................................................... 39 CHAPTER 8: STATISTICAL CONSIDERATIONS .......................................................................................... 40 8.1 General Statistical Considerations...................................................................................................... 40 8.2 Statistical Hypotheses......................................................................................................................... 40 8.3 Sample Size ........................................................................................................................................ 40 8.4 Outcome Measures ............................................................................................................................. 40 8.5 Analysis Datasets ............................................................................................................................... 41 8.6 Analysis of Endpoints ........................................................................................................................ 41 8.6.1 Analysis of the Safety Event Endpoints ....................................................................................... 41 8.6.2 Analysis of Other Safety Endpoints ............................................................................................. 42 8.6.3 Analysis of CGM Endpoints ........................................................................................................ 42 8.6.4 Analysis of Late Bolus Meal Challenges ..................................................................................... 42 8.6.4.1 Late Bolus Meal Challenge Safety and CGM Subgroup Analysis ...................................... 42 8.6.4.2 Time to Intervention Analysis ............................................................................................. 43 8.6.4.3 Number of interventions analysis ........................................................................................ 43 8.7 Intervention Adherence ...................................................................................................................... 43 8.8 Protocol Adherence and Retention ..................................................................................................... 44 8.9 Baseline Descriptive Statistics ........................................................................................................... 44 8.10 Additional Tabulations and Analyses............................................................................................... 44 8.11 Device Issues .................................................................................................................................... 44 8.12 Planned Interim Analyses ................................................................................................................. 44 8.13 Subgroup Analyses ........................................................................................................................... 45 8.14 Multiple Comparison/Multiplicity ................................................................................................... 45 B5

 
   8.15 Handling of Missing Data ................................................................................................................ 45 8.16 General Statistical Considerations.................................................................................................... 45 CHAPTER 9: DATA COLLECTION AND MONITORING............................................................................... 46 9.1 Case Report Forms and Other Data Collection .................................................................................. 46 9.2 Study Records Retention .................................................................................................................... 46 9.3 Quality Assurance and Monitoring .................................................................................................... 46 9.4 Protocol Deviations ............................................................................................................................ 47 CHAPTER 10: ETHICS/PROTECTION OF HUMAN PARTICIPANTS ............................................................ 48 10.1 Ethical Standard ............................................................................................................................... 48 10.2 Institutional Review Boards ............................................................................................................. 48 10.3 Informed Consent Process ................................................................................................................ 48 10.3.1 Consent Procedures and Documentation ................................................................................... 48 10.3.2 Participant and Data Confidentiality .......................................................................................... 48 10.3.3 Future Use of Stored Specimens and Data ................................................................................. 49 CHAPTER 11: REFERENCES ....................................................................................................................... 50    
B6

 
1 LIST OF ABBREVIATIONS   ABBREVIATION DEFINITION ADE Adverse Device Effect AE Adverse Event AID Automated Insulin Dosing BGM Blood Glucose Meter BMI Body Mass Index CFR Code of Federal Regulations CGM Continuous Glucose Monitoring  CLC Closed-Loop Control DCCT Diabetes Control & Complications Trial DKA Diabetic Ketoacidosis eCRF Electronic Case Report Form FDA Food and Drug Administration GCP Good Clinical Practice HbA1c Hemoglobin A1c ICF Informed consent form ICH International Conference of Harmonisation IDE  Investigational Device Exemption IRB Institutional Review Board RBM Risk-Based Monitoring SAE Serious Adverse Event T1D Type 1 Diabetes UADE Unanticipated Adverse Device Effect  
B7

 
   Site Principal Investigator Statement of Compliance Protocol Identifying Number: TP-0011713 Protocol Name: Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Protocol Version / Date: 3.0 / 20 SEP 2022  The Principal Investigators (undersigned) hereby declare that they have read this protocol and agree to its contents. This trial will be carried out in accordance with the principles of Good Clinical Practice (GCP) and as required by the following, as applicable: United States (US) Code of Federal Regulations (CFR) (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812). By written consent to this protocol, the investigators agree to the above and to fully co-operate with all monitoring and audits in relation to this trial by allowing direct access to all documentation, including source data, by authorized individuals representing Tandem Diabetes Care, Inc., IRBs and/or by the US Federal, State and local regulatory authorities.  Investigator Name: ___________________________________________  Investigator Signature: ________________________________________  Date (DD/MMM/YYYY): ______________________________________  
B8

 
 PROTOCOL SUMMARY Study Sponsor Tandem Diabetes Care, Inc. Protocol Number TP-0011713 Protocol Title Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Précis This feasibility study is a prospective, randomized, two-period crossover multi-center study of 2 weeks of home use of Control-IQ 1.5 technology (run-in period), followed by 2 weeks of home use of Control-IQ 2.0 technology at one target, followed by 2 weeks of home use of Control-IQ 2.0 at another target. This automated insulin dosing (AID) system will be evaluated in multiple age groups, with late bolus meal challenges. Products t:slim X2 insulin pump with Control-IQ technology 1.5 (Run-In Period) t:slim X2 insulin pump with Control-IQ technology 2.0 (Treatment Periods) Objectives The objectives of the study are to assess safety of and explore glycemic outcomes with Control-IQ technology 2.0 in adults, children and preschoolers with type 1 diabetes using different targets and after late bolus meal challenges. Number of Sites Up to 6 clinical sites in the US. Study Design Randomized sequence, prospective safety study Number of Participants Up to 100 participants signing consent to use the study devices, so that at least 72 complete the study (at least 30 participants age 14+, at least 30 participants age 6-13, and at least 12 participants age 2-5), plus local contacts for adult participants.  Enrollment goal is at least 50% of all participants in each age group have an HbA1c at baseline of ≥ 7.5%.                                                                                                                             Participant Population: Eligibility to enroll in the study will be assessed based on the following inclusion criteria: 1. Age 2 to ≤ 81 years 2. Diagnosis of type 1 diabetes for at least 1 year, or at least 6 months for age 2-5 years at enrollment 3. Prior Dexcom CGM user, with at least 11 of the prior 14 days of CGM use available for download at the screening visit to confirm eligibility 4. Total Daily Insulin Dose (TDD) at least 2 units/day 5. Weight ≥ 20 lbs 6. HbA1c ≤ 10.5% 7. For participants <18 years old, living with one or more parent/legal guardian knowledgeable about emergency procedures for severe hypoglycemia, present with the participant during and for 5 hours (3 hours for participants age 2-5) after the meal challenges, and willing to use the Dexcom Follow app (with push notifications turned on) for the duration of the study.  8. For participants ≥18 years old, availability of a local contact who has access to the study participant, knows their whereabouts, can be available to assist during the late bolus meal challenges, agrees to be promptly available if contacted by study staff, and willing to use the Dexcom Follow app (with push notifications turned on) for the duration of the study. If the participant lives alone, the local contact must live within 30 minutes and have access to the subject overnight.  9. Investigator has confidence that the participant and/or parent/guardian can successfully operate all study devices and is capable of adhering to the protocol. 10. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study devices, with no use of long-acting basal insulin injections, or inhaled insulin with the study devices. 11. Have current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (site will provide prescription if they do not have one) B9

 
 12. Willing and able to perform the study late bolus meal challenges. Eligibility to enroll in the study will be assessed based on the following exclusion criteria:  1. More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months 2. More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months 3. Inpatient psychiatric treatment in the past 6 months  4. For Female: Currently pregnant or planning to become pregnant during the time period of study participation a. A negative pregnancy test will be required for all females of child-bearing potential b. Counseling on appropriate birth control options will be provided to all females of child-bearing potential 5. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 6. Hemophilia or any other bleeding disorder 7. Hemoglobinopathy 8. History of heart, liver, lung or kidney disease determined by investigator to interfere with the study 9. History of allergic reaction to Humalog or Novolog 10. Use of any medications determined by investigator to interfere with study 11. Significant chronic kidney disease (which could impact CGM accuracy in investigator’s judgment) or hemodialysis 12. Concurrent use of any medication that could interfere with the study CGM, such as hydroxyurea 13. History of adrenal insufficiency 14. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated 15. History of gastroparesis 16. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk 17. Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for during the time period of study participation 18. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial                                                      Participant Duration Approximately 6-12 weeks 
B10

 
1 Study Endpoints The adult, pediatric and preschool populations will be combined for the analysis of primary and secondary endpoints. Separate analyses also will be performed for the adult, pediatric and preschool cohorts for the primary and secondary endpoints. CGM data collected during the challenge periods will not contribute to overall analysis of CGM metrics. The three study time periods are the Run-In period with Control-IQ technology 1.5, treatment period with Control-IQ technology 2.0 at the standard target, and treatment period with Control-IQ technology 2.0 at the lower target, where the order of treatment periods will be randomized. Primary Endpoints: 1. Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed for treatment) during study compared with data on severe hypoglycemic events reported by T1D Exchange clinic registry over a 3-month time period 2. Diabetic ketoacidosis during study compared with data on DKA events reported by T1D Exchange clinic registry over a 3-month time period 3. Number of unanticipated adverse device effects 4. Number of other serious device-related adverse events Secondary Endpoints: 1. All device-related adverse events 2. CGM hypoglycemia outcomes, compared between the three study time periods  a. Overall % time <54 mg/dL b. Overall % time <70 mg/dL 3. Times in ranges-overall (70-180 mg/dL, >180 mg/dL, >250 mg/dL, 70-140 mg/dL) compared between the three study time periods 4. Mean glucose compared between the three study time periods 5. Overall variability (CV and SD) compared between the three study time periods 6. Secondary endpoints 2 – 5 compared during daytime and nighttime, across the three study time periods  7. Secondary endpoints 2 - 5 as well as adverse events, during the study meal challenge periods, for late bolus feature use compared to normal bolus in the meal challenges. 8. Time to intervention for hypo- or hyperglycemia during the study meal challenge periods, for late bolus feature use compared to normal bolus in the meal challenges. 9. Number of interventions for hypo- or hyperglycemia during the study meal challenge periods for late bolus feature use compared to normal bolus in the meal challenges. 10. Subgroup Analysis for all metrics by age cohort, baseline HbA1c cohort, and target activity use (standard target, lower target, sleep activity, exercise activity) Protocol Overview/Synopsis After consent is signed, eligibility will be assessed.   Run-In Period: Participants will return to clinic to undergo device training with the study CGM and a Control-IQ technology 1.5 pump. Training for both devices may be combined, or depending on comfort level of investigator and participant, participants may return for a second session to complete device training and begin the Control-IQ 1.5 run in period. The run-in period will end after 2 weeks of Control-IQ technology 1.5 use. Participants will have a phone follow up phone call at 1 day, 3 days and 1 week after starting Control-IQ technology 1.5 use, and will return to clinic at two weeks to commence Control-IQ technology 2.0 training.  Treatment Periods: Participants will then use the study pump with Control-IQ technology 2.0 for 4 weeks during the study period (2 weeks with a lower target of 90-130 mg/dL, and 2 weeks with a standard target of 112.5-160 mg/dL, in random order). Participants will have a follow up contact at 1 B11

 
day, 3 days and 1 week into Control-IQ 2.0 use, a follow-up visit at 2 weeks to switch targets, a follow up contact 3 days later and 1 week after switching targets, and a follow up visit at 4 weeks to end the study. Participants will use the t:slim X2 insulin pump with Control-IQ technology 2.0 turned on. It is acceptable to use manual mode when there is a loss of CGM data. Each participant will perform 2 late bolus meal challenges in each two-week period, contacting the study clinical site before and after each challenge. An assessment of adverse events, using open ended questions to capture hyperglycemic and hypoglycemic events, and their underlying cause and relationship to the study device or other parts of the system (such as the infusion set), will occur at all visits/contacts. Study Safety Plan:  Participants will be given a blood glucose and ketone meter to use throughout the study, and will be trained on their use by qualified staff.  BGM readings will be performed in accordance with the participant instruction sheet and per CGM manufacturer instructions. Ketone readings will be performed per the participant instruction sheet. Site investigators may adjust insulin delivery profile settings as needed throughout the study in accordance with their clinical practice. Real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for the first ten 6-13 year old participants to begin use of the lower target (90-130 mg/dL) for the first week of Control-IQ 2.0 use at that target. In addition, real-time CGM alerts will be sent to study staff providers for all 2-5 year old participants throughout their use of Control-IQ 2.0 technology (all 4 weeks).  
B12

 
SCHEMATIC OF STUDY DESIGN  
B13

 
SCHEDULE OF STUDY VISITS AND PROCEDURES 
1Late meal bolus challenges will occur throughout Control-IQ 2.0 use in the treatment period, with 2 challenges in each 2 week period. 2Pregnancy test at Control-IQ 1.5 device training does not need to be repeated if screening and Control-IQ 1.5 training visits are performed on the same day. Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 UV   Run-In Period Treatment Period  Screening Visit Control-IQ 1.5 Training Visit Control-IQ 1.5 Run-In Period Control-IQ 2.0 Training Control-IQ 2.0 Treatment Period 1 Control-IQ 2.0 Treatment Period 2    Up to 2 weeks after screening 1d 3d 1w 2w 1d 3d 1w 2w 1d 3d 1w 2w (Final  Visit) UV Visit (V) or Contact (C) V V C C C V C C C V C C C V V/C Informed Consent X               Eligibility Assessment X               Medical history/ physical exam X               Height, weight, blood pressure and pulse X               HbAlc (POC or local lab) X               Pregnancy test (females of child-bearing potential) X X2    X          Questionnaires      X    X    X  Assessment of Device Use X     X          Study system training  X    X    X      Late Meal Bolus Challenges1        X  X  AE/Device Issue Assessment   X X X X X X X X X X X X X Upload and Review Study Device Data   X X X X X X X X X X X X X 
B14

 
Chapter 1: Background Information 1 1.1 Introduction 2 1.1.1 Disease Background 3 Type 1 diabetes affects 1.25 million people in the United States. Approximately 70% of individuals with 4 type 1 diabetes report poor metabolic control, and do not meet the American Diabetes Association’s 5 recommended goal of hemoglobin A1c (HbA1c) level of 7.0%. These findings indicate the need for better 6 approaches to type 1 diabetes management. 7 1.1.2 Tandem X2 Insulin Pump with Control-IQ Technology 8 The Tandem X2 insulin pump with Control-IQ technology is an FDA-approved closed-loop control 9 (CLC) system based on the control algorithm developed and initially tested in the University of 10 Virginia’s DiAs system and then implemented in the inControl system (TypeZero, Technologies, Inc.). 11 Use of the Control-IQ system has been extensively tested in adults and children with type 1 diabetes 12 (T1D), demonstrating its efficacy and safety when used with insulin lispro (Humalog) or insulin aspart 13 (Novolog).1,2 The system is currently approved for ages 6 years and older and its use in younger children 14 is currently being studied (clinical trials.gov [STUDY_ID_REMOVED]). There are over 150,000 users of the 15 system since it became commercially available in 2020. A recent evaluation of real-world use of the 16 system in 9,451 users age >6 years with at least 12 months of system use found results comparable to 17 those found in the randomized trials.3  18 Since the initial approval of the system, modifications have been made in the software, which is referred 19 to as version 1.5. These modifications include modest usability improvements and other enhancements 20 intended to further reduce risk. The Control-IQ 1.5 system also allows for a wider range of inputs to 21 weight and total daily insulin, allowing it to be used by a broader group of individuals with diabetes, and 22 has been evaluated in numerous clinical trials ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]). 23 Control-IQ technology 2.0 incorporates all the changes in version 1.5, and adds several new features 24 intended to improve time-in-range with no significant increase in hypoglycemia. These changes also 25 include features to improve safety around exercise, and to make bolusing for meals safer. Control-IQ 26 technology 2.0 was recently studied in 30 adults and adolescents age 14+, with over 20,000 hours of use, 27 and showed improvements in time in range without increases in hypoglycemia ([STUDY_ID_REMOVED]).  28 1.2 Rationale 29 The objective of this randomized, prospective, two-period crossover study conducted in three age cohorts 30 is to assess safety and explore glycemic outcomes associated with use of Control-IQ technology 2.0 31 including Adults and Adolescents age 14+ years old, children age 6-13 years old, and preschool children 32 age 2-5 years old. Participants will evaluate Control-IQ 2.0 technology using different glycemic targets, 33 as well as perform late bolus meal challenges.  34 1.3 Potential Risks and Benefits 35 Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 36 handled to minimize this risk. Hypoglycemia, hyperglycemia and ketone formation are always a risk in 37 participants with type 1 diabetes and participants will be monitored for these events. 38 
B15

 
1.3.1 Known Potential Risks 39 1.3.1.1 Blood Draw 40 A venipuncture and/or fingerstick will be performed to obtain blood for HbA1c measurement. 41 Venipuncture can cause common reactions like pain, bruising, or redness at the sampling site. 42 Less common reactions include bleeding from the sampling site, formation of a small blood clot or 43 swelling of the vein and surrounding tissues, and fainting. A fingerstick frequently causes transient pain 44 and there may be a small, localized bruise, which may be followed by a small scar that may persist for 45 several weeks. The risk of local infection is less than 1 in 1000 with either venipuncture or fingerstick. 46 1.3.1.2 CGM and Pump Catheter Risks 47 There is a small risk of bleeding where the sensor or infusion set is inserted. There is a small risk for 48 developing a local skin infection at the site of CGM sensor placement of pump infusion set placement. 49 This may be associated with swelling, redness and pain; and may require antibiotic therapy. Rarely, a 50 CGM sensor may break and leave a small portion of the sensor under the skin that may cause redness, 51 swelling or pain at the insertion site. 52 Some participants may develop skin irritation or allergic reactions to the adhesives used to secure the 53 CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion. If these 54 reactions occur, different adhesives or “under-taping” (such as with IV 3000, Tegaderm, etc.) will be 55 tried, sites will be rotated frequently, and a mild topical steroid cream or other medication may be 56 required.  57 1.3.1.3 Hypoglycemia 58 As with any person having type 1 diabetes and using insulin, there is always a risk of having 59 hypoglycemia. The frequency of hypoglycemia should be no more and possibly less than it would be 60 as part of daily living. Symptoms of hypoglycemia can include sweating, jitteriness, and not feeling well. 61 There is the possibility of fainting or seizures (convulsions) and that for a few days the participant may 62 not be as aware of symptoms of hypoglycemia. A CGM functioning poorly and significantly over-63 reading glucose values could lead to inappropriate insulin delivery. The study meal challenges, requiring 64 boluses to be delivered late, could increase the risk of hypoglycemia. 65 1.3.1.4 Risk of Hyperglycemia 66 Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 67 extended period or if the pump or infusion set is not working properly. A CGM functioning poorly 68 and significantly under-reading glucose values could lead to inappropriate suspension of insulin delivery. 69 The study meal challenges, requiring boluses to be delivered late, could increase the risk of 70 hyperglycemia. 71 1.3.1.5 Risk of Device Reuse 72 All devices will be used by a single study participant only. There will be no device reuse. 73 1.3.1.6 Potential Risks of the CLC System 74 Even though the study system has been tested prior to this study, there is still a risk that parts of the 75 system may not function properly. The following are possible reasons the system may deliver too much 76 insulin or incorrectly stop insulin delivery: 77 • CGM sensor reads higher or lower than the actual glucose level which increases risk for 78 hypoglycemia and hyperglycemia with automated insulin delivery system; 79 

 
 • Device malfunctions that could produce a suspension of insulin delivery or over delivery of insulin. 80 1.3.1.7 Other Risks 81 Data downloaded from the CGM, pump, and the home glucose and ketone meter will be collected for the 82 study. The downloaded data from the participant’s home devices at the screening visit may include data 83 from the period beyond the last 2 weeks prior to screening. Some people may be uncomfortable with the 84 researchers' having such detailed information about their daily diabetes habits. 85 1.3.2 Benefits 86 Participants may achieve better glucose control than they are currently achieving using their home insulin 87 pump.  88 The individual participant may not benefit from study participation. 89 1.3.3 Risk Assessment 90 Based on the facts that (1) individuals with diabetes experience mild hypoglycemia and hyperglycemia 91 frequently as a consequence of the disease and its management, (2),  mitigations are in place, and have 92 been tested in prior studies using the investigational device system in the home setting, that limit the 93 likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (3) rapid reversal of 94 hypoglycemia and hyperglycemia can be achieved, it is the assessment of the Sponsor that this protocol is 95 an investigation involving a minor increase over minimal risk. In addition, it is the belief of the Sponsor 96 that this study also presents prospect of direct benefit to the participants and general benefit to others with 97 diabetes. 98 1.4 General Considerations 99 The study is being conducted in compliance with the ethical principles that have their origin in the 100 Declaration of Helsinki, with the protocol described herein, and with the standards of Good Clinical 101 Practice (GCP). 102 In accordance with 21 CFR 812.66, the protocol is considered a significant risk device study, due to the 103 fact that the intervention is investigational. Therefore, an investigational device exemption (IDE) from the 104 U.S. Food and Drug Administration (FDA) is required to conduct the study. 105  106 
B17

 
Chapter 2: Study Enrollment and Lead-in Period 107 2.1 Participant Recruitment and Enrollment 108 Enrollment will proceed with the goal of having up to 100 subjects screened, so that at least 72 complete 109 closed loop use (at least 30 participants age 14+, at least 30 participants age 6-13, and at least 12 110 participants age 2-5), plus local contacts for adult participants. 111 Enrollment will be staged, so that at least ten 6-13 year olds will complete the trial before enrolling any 2-112 5 year olds. A trial level safety review with the study coordinating center, sponsor and the site primary 113 investigators will be performed, summarizing the data after the first ten 6-13 year olds who complete this 114 trial. Criteria to begin enrolling 2-5 years will include 1) No UADE’s affecting participant safety, 2) 115 Study Stopping Criteria have not been met overall (total AE’s related to DKA or severe hypoglycemia), 116 3) No safety concerns from all parties and approval from all parties to continue the study. This review 117 will be documented in the trial master file. 118 An enrollment goal is to have at least 50% of all participants in each age group have an HbA1c at baseline 119 of ≥ 7.5%, and to have at least 6 participants age 14-17 years old. 120 Study participants will be recruited from up to 6 clinical centers in the United States without regard to 121 gender, race, or ethnicity. There is no restriction on the number of participants to be enrolled by each site 122 toward the overall recruitment goal.          123 2.1.1 Informed Consent and Authorization Procedures 124 Potential eligibility may be assessed as part of a routine-care examination. Before completing any 125 procedures or collecting any data that are not part of usual care, written or electronic informed consent 126 will be obtained. 127 For potential study participants, the study protocol will be discussed with the potential study participant 128 by study staff. The potential study participant will be given the Informed Consent Form to read. Potential 129 study participants will be encouraged to discuss the study with family members and their personal 130 physicians(s) before deciding whether to participate in the study.  131 For participants less than 18 years of age, a parent/legal guardian will be provided with the Informed 132 Consent Form to read and will be given the opportunity to ask questions. Assent will be obtained from 133 subjects 7 to <18 years of age. A legally authorized representative (parent/guardian) must sign the consent 134 form for all participants less than 18 years of age, and agree to the CGM monitoring requirements of the 135 study. 136 A copy of the consent/assent form will be provided to the participant and if the participant is a minor, 137 his/her parent/guardian, and another copy will be added to the participant’s study record. 138 As part of the informed consent process, each participant will be asked to sign an authorization for 139 release of personal information. The investigator, or his or her designee, will review the study-specific 140 information that will be collected and to whom that information will be disclosed. After speaking with 141 the participant and/or parent/guardian, questions will be answered about the details regarding 142 authorization. 143 A local contact is required for all participants > 18 years of age. Each local contact must sign the local 144 contact consent form, and agree to the CGM monitoring requirements of the study. 145 A participant is considered enrolled when the informed consent form has been signed. 146 
B18

 
2.2 Participant Eligibility Criteria 147 2.2.1 Inclusion Criteria 148 Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the 149 study. 150 1. Age 2 to ≤ 81 years 151 2. Diagnosis of type 1 diabetes for at least 1 year, or at least 6 months for age 2-5 years at 152 enrollment 153 3. Prior Dexcom CGM user, with at least 11 of the prior 14 days of CGM use available for 154 download at the screening visit to confirm eligibility 155 4. Total Daily Insulin Dose (TDD) at least 2 units/day 156 5. Weight ≥ 20 lbs 157 6. HbA1c < 10.5% 158 7. For participants <18 years old, living with one or more parent/legal guardian knowledgeable 159 about emergency procedures for severe hypoglycemia, present with the participant during and for 160 5 hours (3 hours for participants age 2-5) after the meal challenges, and willing to use the 161 Dexcom Follow app (with push notifications turned on) for the duration of the study. 162  163 8. For participants ≥18 years old, availability of a local contact who has access to the study 164 participant, knows their whereabouts, can be available to assist during the late bolus meal 165 challenges, agrees to be promptly available if contacted by study staff, and willing to use the 166 Dexcom Follow app (with push notifications turned on) for the duration of the study. If the 167 participant lives alone, the local contact must live within 30 minutes and have access to the 168 subject overnight.  169  170 9. Investigator has confidence that the participant and/or parent/guardian can successfully operate 171 all study devices and is capable of adhering to the protocol. 172 10. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study devices, with no 173 use of long-acting basal insulin injections, or inhaled insulin with the study devices. 174 11. Have current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will 175 provide prescription if they do not have one). 176 12. Willing and able to perform the study late bolus meal challenges. 177 2.2.2 Exclusion Criteria 178 Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 179 participation. 180 1. More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months 181 2. More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months 182 3. Inpatient psychiatric treatment in the past 6 months 183 4. For Female: Currently pregnant or planning to become pregnant during the time period of study 184 participation 185 • A negative pregnancy test will be required for all females of child-bearing potential  186 B19

 
• Counseling on appropriate birth control options will be provided to all females of child-187 bearing potential 188 5. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, 189 GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 190 6. Hemophilia or any other bleeding disorder 191 7. Hemoglobinopathy 192 8. History of heart, liver, lung or kidney disease determined by investigator to interfere with the 193 study 194 9. History of allergic reaction to Humalog or Novolog 195 10. Use of any medications determined by investigator to interfere with study 196 11. Significant chronic kidney disease (which could impact CGM accuracy in investigator’s 197 judgment) or hemodialysis 198 12. Concurrent use of any medication that could interfere with the study CGM, such as hydroxyurea 199 13. History of adrenal insufficiency 200 14. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not 201 appropriately treated 202 15. History of gastroparesis 203 16. A condition, which in the opinion of the investigator or designee, would put the participant or 204 study at risk 205 17. Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for 206 during the time period of study participation 207 18. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., or 208 having a direct supervisor at place of employment who is also directly involved in conducting the 209 clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is 210 directly involved in conducting the clinical trial 211 2.3 Visit 1: Screening Visit 212 After informed consent has been signed, a potential participant will be evaluated for study eligibility 213 through the elicitation of a medical history, performance of a physical examination by study personnel 214 and local laboratory testing if needed to screen for exclusionary medical conditions. 215 2.3.1 Data Collection and Testing 216 A standard physical exam (including vital signs and height and weight measurements) will be performed 217 by the study investigator or designee (a physician, fellow, nurse practitioner or a physician assistant). 218 Height, weight and vital signs may be recorded by appropriately delegated office staff. 219 The following procedures will be performed/data collected/eligibility criteria checked and documented: 220 • Inclusion and exclusion criteria assessed 221 • Demographics (age or year and month of birth for preschool participants, sex, race and ethnicity and 222 socioeconomic information ) 223 • Subject initials to verify eCRF entry is associated with the correct individual  224 B20

 
• Contact information (retained at the site and not entered into study database) 225 • Medical history 226 • Concomitant medications 227 • Physical examination to include: 228  Weight, height 229  Vital signs including measurement of blood pressure and pulse 230 • Blood draw (venipuncture or fingerstick) for local HbA1c measurement 231 • Urine pregnancy test for all females of childbearing potential who are premenopausal and not 232 surgically sterile 233 • Current device download, to include insulin pump and CGM device data, for up to the last two weeks 234 of data if available 235 Screening procedures will last approximately 1-2 hours. The screening visit must occur in clinic and 236 cannot be performed remotely. 237 2.4 Screen Failures 238 Individuals who do not initially meet study eligibility requirements may be rescreened one more time at a 239 later date per investigator discretion. 240  241 
B21

 
Chapter 3: Device Training and Study Visits 242 3.1 Visit 2: Control-IQ 1.5 Training Visit 243 After screening, participants will have a clinic visit at which they will undergo CGM and Control-IQ 1.5 244 technology pump device training.  245 The device training visit should be completed within 2 weeks of screening, and may be performed the 246 same day as the screening visit. If not completed within 2 weeks of screening, re-review of screening 247 results by the investigator should be performed, who may ask for repeated testing as per investigator 248 judgement. The device training visit may be extended over the course of more than 1 session if needed. 249 The device training visit must occur in clinic and cannot be performed remotely. 250 A urine pregnancy test for all females of childbearing potential (postmenarchal) who are premenopausal 251 and not surgically sterile will be completed. 252 Participants will receive supplies for blood glucose and ketone testing. Quality Control (QC) testing will 253 be performed on the meters before they are dispensed. 254 All participants will use study supplied Control-IQ technology 1.5 pumps during the study run-in phase, 255 even if they are current Control-IQ technology users. Pump settings may be transferred over from the 256 participant’s prior pump, or for current multiple daily injection users, can be started per the guidance on 257 the device training checklist. 258 3.1.1 Training on System Use 259 All participants will receive study system training from qualified staff, to include CGM and Control-IQ 260 training. 261 At a minimum training will include the following: 262 • Calibration of the CGM in accordance with manufacturer labeling 263 • Procedures for treating severe hypoglycemia 264 • Procedures for identifying potential infusion set failure and steps to take including the checking of the 265 blood ketone level and changing the infusion set 266 • Use of the security PIN on the insulin pump will be required for anyone who is not entirely 267 responsible for their own diabetes care, to include all 2-5 year olds, and those 6 years of age or older 268 who may be only partially responsible for their own diabetes management. 269 The participant will be given a User Guide as a reference as well as Hypoglycemia and Hyperglycemia 270 Treatment Guidelines as part of the Study Participant Instruction Sheet. The device training checklist for 271 CGM and the Control-IQ 1.5 pump will be completed by qualified study staff. 272 Participants will be instructed to download the study device prior to each phone contact or office visit. 273 The participant will be instructed to use the system in closed-loop mode except 1) when no calibrated 274 CGM sensor is available or 2) if insulin is delivered by any means other than the study pump (e.g. 275 injection of subcutaneous insulin via syringe in the event of infusion site failure). If insulin is delivered 276 by any means other than the study pump, participant will be instructed to turn off Control-IQ for the next 277 four hour and until CGM glucose is < 180 mg/dL. 278 The participant will also be instructed to contact study staff during periods of illness with an elevated 279 temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), periods of significant illness, or during 280 periods of use of medications such as epinephrine for the emergency treatment of a severe allergic 281 reaction or asthma attack. Participants will contact study staff if treatment with oral or injectable 282 B22

 
glucocorticoids is needed to determine if and for how long closed-loop use should be temporarily 283 discontinued. Given the short period of use of each aspect of the system, participants may be asked to end 284 participation in the study if the investigator judges Control-IQ technology use must be stopped for more 285 than a few days. 286 Participants will be provided with contact information and will be asked to call the study clinical staff 287 for any health-related issues and for technical issues with the system. Participants may use the study 288 pump without Control-IQ activated and study CGM during periods of component disconnections or 289 technical difficulties. 290 Participants may use available manufacturer-provided CGM software and features of the study CGM 291 related to mobile data access or remote monitoring, but will be instructed not to use any third-party 292 components for this purpose. The t:connect mobile app from Tandem Diabetes Care will not be 293 available for use during the trial, and will not pair to the study pumps. 294 Study staff will discuss with the participant that routine contact is required as per the study visit schedule 295 and will make arrangements with the participant for the contacts.  296 Participants may complete the device training visit in more than 1 session if necessary. 297 3.1.2 Training on Management of Hypoglycemia 298 The t:slim X2 with Control-IQ system will issue a predictive hypoglycemia alert (Control-IQ Low Alert) 299 when the system predicts BG <70 mg/dL within the next 15 minutes (<80 mg/dL when exercise mode is 300 activated). Participants will be permitted to change the CGM low glucose threshold alert setting on their 301 device (or Dexcom mobile app), but will be instructed to choose a value no less than 70 mg/dL. 302 If the participant receives a Control-IQ Low Alert, a message appears on the user interface that is 303 accompanied by vibration followed by vibrations and/or sound if not acknowledged by the user in 5 304 minutes. This alert remains on the screen until acknowledged by the participant. The user is prompted 305 to test blood glucose and treat with carbohydrate. 306 The participant (and /or parent/guardian) will be instructed that if severe hypoglycemia occurs, the study 307 pump’s insulin delivery should be suspended and glucagon administered if the participant is unable to 308 consume carbohydrate. 309 Participants will be required to have a home glucagon emergency kit. Participants who currently do not 310 have one will be given a prescription for the glucagon emergency kit. 311 3.1.3 Training on Management of Hyperglycemia 312 The t:slim X2 with Control-IQ system will issue a predictive hyperglycemia alert (Control-IQ High Alert) 313 when the system has increased insulin delivery, but detects a CGM value above 200 mg/dL and does not 314 predict the value will decrease in the next 30 minutes. During the course of the study, participants will be 315 permitted to change the CGM high glucose threshold alert setting on their device or mobile app, but will 316 be instructed to choose a value no greater than 300 mg/dL. 317 If the participant receives a Control-IQ High Alert, a prompt appears on the user interface to check the 318 site for occlusion and test blood glucose. 319 If a participant’s CGM reading is >300 mg/dL for more than 60 minutes or is ≥400 mg/dL at any point, 320 the participant will be instructed to take the following steps: 321 • Perform a blood glucose meter check. 322 • If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 323 
B23

 
• If the ketone level is ≥ 0.6 mmol/L (or ≥ 2.5 mmol\L at any time), take correction insulin, change 324 insulin (pump) infusion site and contact study staff. Continue to monitor their glucose and blood 325 ketone levels until they return to normoglycemia and ketones are < 0.6 mmol/l. 326  If ketones are <0.6 mmol/l, participants will be advised to continue to monitor their glucose 327 until it returns to normoglycemia and to repeat the ketone measurement in 90 minutes if 328 necessary 329 • If correction insulin is administered via insulin syringe, turn Control-IQ off for four hours and until 330 glucose level has returned to <180 mg/dL. 331 3.2 Visits 3, 4 and 5: Control-IQ 1.5 follow up contacts 332 Following the Control-IQ 1.5 Training Visit, participants will use the study Control-IQ 1.5 pump and 333 study CGM for ~2 weeks during the study Run-In Period. A contact will occur at 1 day (+12 hours), 3 334 days (1 day) to review adverse events as well as discuss infusion set care, and another phone call at 7 335 days (2 days). Participants will then return to clinic in approximately 2 weeks (3 days). 336 3.3 Visit 6: Control-IQ 2.0 Training Visit 337 After participants complete the run-in, they will return for the Control-IQ 2.0 training visit, and switch to 338 the Control-IQ 2.0 study pump after training by qualified staff.  339 Control-IQ 2.0 allow for selection of different glycemic targets, as well as toggling autoboluses in 340 standard and exercise activity. The late bolus feature will also be available. 341 Participants will be randomized to use either a daytime 30-min predictive glucose target of 90-130 mg/dL 342 or 112.5 to 160 mg/dL for the first two-week period, then switch to the other target after 2 weeks.  343 In the training visit, participants will: 344 1) Select the appropriate target in clinic on their study pump per the randomization, and will be 345 instructed by study staff to use the assigned glycemic target during each two week period.  346 2) Be instructed that autoboluses will default to on during normal activity, and off during exercise 347 activity.  348 3) Be reminded again that use of the security PIN on the insulin pump will be required for anyone 349 who is not entirely responsible for their own diabetes care, to include all 2-5 year olds, and those 350 6 years of age or older who may be only partially responsible for their own diabetes management. 351 4) Be instructed that sleep activity will be required during Control-IQ 2.0 use. A sleep schedule 352 should be programmed into the pump for use each night. Participants will be instructed to disable 353 sleep or adjust the schedule on the nights of the late bolus meal challenges, then re-enable sleep 354 activity as soon as the challenges are over, so it is used the rest of the night. 355 5) Review prior training guidelines from the Control-IQ technology 1.5 training visit, and be taught 356 how the new features are different in Control-IQ technology 2.0. 357 6) Review the study meal late bolus challenges, to be performed twice in each two week period. 358 Participants may also use late bolus as desired outside of the challenges. 359 The participant will be given a User Guide as a reference as well as review the Hypoglycemia and 360 Hyperglycemia Treatment Guidelines as part of the Study Participant Instruction Sheet. The study device 361 training form will be completed. 362 Participants will be instructed to download the study device prior to each phone contact or office visit. 363 
B24

 
Participants may use available manufacturer-provided CGM software and features of the study CGM 364 related to mobile data access or remote monitoring, but will be instructed not to use any third-party 365 components for this purpose. The t:connect mobile app from Tandem Diabetes Care will not be 366 available for use during the trial, and will not pair to the study pump. 367 The device training checklist for the Control-IQ 2.0 pump will be completed by qualified study staff. 368 A urine pregnancy test for all females of childbearing potential who are premenopausal and not surgically 369 sterile will be performed. 370 Study staff will discuss with the participant that routine contact is required as per the study visit schedule 371 and will make arrangements with the participant for the contacts.  372 Clinical staff will verify with participants at each contact that the correct glycemic targets are being used. 373 Contacts for the study meal challenges will occur throughout the study Treatment Period. 374 Baseline INSPIRE questionnaire for pediatric participants age 8-17, for adult participants age 18+, and 375 for parents of pediatric participants age 2-17 will be completed. 376 3.4 Study Contacts in the Treatment Period with Control-IQ 2.0 Technology 377 Participants will have a phone (or video-conference) follow-up visit at 1 day, 3 days and 1 week, a clinic 378 follow-up visit at 2 weeks, a phone follow-up visit at 3 days and 1 week after switching glycemic targets, 379 and a final clinic visit at 2 weeks after switching glycemic targets, within the windows specified below. 380 TARGET DAY/WEEK VISIT OR PHONE TARGET WINDOW (AROUND TARGET DAY/WEEK) Visit 6: Control-IQ 2.0 Training Visit V 2 weeks (3 days) after Visit 2 Visit 7: 1 days after visit 6 P +12 hours Visit 8: 3 days after visit 6 P +1 day Visit 9: 1 week after visit 6 P +2 days Visit 10: 2 weeks after visit 6 (switch targets) V +3 days Visit 11: 1 day after visit 10 P +12 hours Visit 12: 3 days after visit 10 P +1 days Visit 13: 1 week after visit 10 P +2 days Visit14: 2 weeks after visit 10 V +3 days If necessary, visits should be completed out-of-window rather than missed. A visit is not considered 381 missed until the next visit/phone window opens.  382 The goal will be for all participants to complete all scheduled visits. However, participants who 383 (because of unforeseen circumstances or due to changes in contact precautions that may be needed 384 during the evolving COVID-19 pandemic) are unable or unwilling to return for all follow-up visits 385 will be permitted to return for key visits only (Visits 1, 2 and 6) as an alternative to withdrawal from the 386 study. Remote (phone) visits will still be performed as scheduled. When a participant is placed into this 387 status, remote visits for visits 10 and 14 will not be recorded as protocol deviations. 388 Additional phone and office visits may occur as needed. 389 For the in clinic visits at the end of each two week treatment period, if a clinical site believes these visits 390 need to be performed remotely, the following approvals must be obtained prior to conducting the visit 391 remotely: 392 5

 
• Sponsor approval for the reason the visit cannot be performed in person 393 • Investigator approval at the site level for the reason the visit cannot be performed in person 394 In addition, all study procedures listed in section 3.4.1 are to be completed, including upload of the study 395 device and review of the device data. If the final visit is performed remotely, participant will mail in their 396 study devices, and investigators will remotely supervise transition back to their home diabetes treatment 397 plan. 398 3.4.1 Procedures at all Study Visits 399 The following procedures will be performed at each visit, unless otherwise specified: 400 • Review of study device data 401 • Assessment of compliance with study device use by review of any available device data 402 • Assessment of device issues that have occurred 403 • Assessment of adverse events, using open ended questions to capture hyperglycemic and 404 hypoglycemic events, and their underlying cause and relationship to the study device or other parts of 405 the system (such as the infusion set). 406 • Review of ongoing study late bolus meal challenges when in the treatment period 407 • Baseline INSPIRE questionnaire for pediatric participants age 8-17, for adult participants age 18+, 408 and for parents of pediatric participants age 2-17 will be completed at visit 6 409 • Post Assessment INSPIRE questionnaire for pediatric participants age 8-17, for adult participants age 410 18+, and for parents of pediatric participants age 2-17 will be completed at visits 10 and 14 411 • SUS Scale will be completed at visits 10 and 14 412 • Study Specific Questionnaire will be completed at visits 10 and 14 413 At the final visit (or at subject withdrawal), the study staff will then supervise the participants transition 414 back to their standard of care therapy as follows: 415 • Study staff will re-evaluate the subject’s baseline therapy doses, noting changes in basal rates, 416 carbohydrate ratios, and correction factors in use at the end of the trial. For prior CSII users, the 417 study investigator will supervise and confirm the entry of settings in the insulin delivery profile of 418 the participant’s home pump at the end of the study. 419 • For those subjects using basal insulin, doses will be adjusted to best match the current daily 420 insulin requirements from CSII use, typically = (total daily dose + 20%)/2, with further 421 modification as per clinical site usual practice.  422 • Participants must have two CGM or fingerstick BG values, separated by at least 15 minutes, that 423 must be above 80 mg/dL prior to discharge from the clinic for the final visit. In addition, CGM 424 trend arrow must not be going down at the time of discharge. 425 • Study staff will confirm subjects have carbohydrates on hand for their drive back home, and 426 instruct subjects to check their glucose levels when they arrive at home, prior to bedtime, and at 427 least one time overnight on the first night to monitor for hypoglycemia, reminding subjects that 428 insulin on board can be active for the next few hours even after stopping their pump. 429 
B26

 
3.5 Unscheduled Visits 430 Participants may have unscheduled visits during the study period if required for additional device training 431 or other unanticipated needs per the study investigator discretion. 432 3.6 Late Bolus Meal Challenges 433 Participants will complete two late bolus meal challenges during each two week treatment period. 434 Procedures are described in section 5.1. 435 3.7 Adjustments in Insulin Pump Settings 436 Insulin and glucose data from the screening visit, as well as follow up visits, will be reviewed and the site 437 investigator may adjust insulin delivery profile settings as needed in accordance with their clinical 438 practice. 439 3.8 Early Discontinuation of Study Device 440 If the participant cannot be reached for scheduled study contacts, the participant’s other contact methods 441 will be utilized. Participants who are not compliant with the arranged contacts on two separate occasions 442 may be discontinued at the discretion of the investigator. Participants who discontinue the study device 443 prior to the final visit, either by choice or by investigator decision, will be asked to come for an end of 444 study visit and then will be dropped from the study.  445 3.9 Remote Monitoring 446 Real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for the first ten 6-13 year 447 old participants to begin use of the lower target (90-130 mg/dL) for the first week of Control-IQ 2.0 use at 448 that target. This requirement will only be removed for future participants in this age group after the first 449 ten participants finish the first week of use of the lower target, and no safety concerns arise, where: 450 1) No severe hypoglycemia events related to algorithm delivered automated insulin dosing occur 451 that required study staff intervention because the participant was not aware/treating 452 appropriately. 453 2) No severe hyperglycemic events related to algorithm delivered automated insulin dosing 454 occurred that required study staff intervention because the participant was not aware/treating 455 appropriately.  456 In addition, real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for all 2-5 year 457 old participants throughout their use of Control-IQ 2.0 technology (all 4 weeks). 458 
B27

 
Chapter 4: Study Devices and Drugs 459 4.1 Study Devices 460 4.1.1 Insulin Pump 461 For the run in period, participants will use a study provided Tandem t:slim X2 with Control-IQ 1.5 462 technology (Investigational Device). For the treatment period, participants will use a study provided 463 Tandem t:slim X2 with Control-IQ 2.0 technology (Investigational Device). 464 4.1.2 Continuous Glucose Monitoring 465 The study CGM is the commercial version of the Dexcom G6, which includes a transmitter and sensors. 466 The CGM sensor will be replaced at least once every 10 days. 467 4.1.3 Blood Glucose Meter 468 The study blood glucose meter is the Contour® NEXT (Ascencia Diabetes Care). 469 Blood glucose levels will be measured using the study’s blood glucose meter (glucometer) and the 470 CGM device will be calibrated if needed using the study glucometer and strips in accordance with the 471 manufacturer’s labeling. 472 4.1.4 Ketone Meter 473 The study blood ketone meter is the Precision Xtra Blood Glucose and Ketone Monitoring System 474 (Abbott Diabetes Care). 475 Blood ketone levels will be measured when needed to evaluate prolonged hyperglycemia. The blood 476 glucose meter component of the Precision Xtra device will not be used. 477 4.2 Study Device and Drug Accountability Procedures 478 Device accountability and inventory will be documented to include detailed inventory records of the study 479 CGM supplies, and Tandem insulin pump system. 480 4.3 Participant Access to Study Device at Study Closure 481 Participant will return all investigational study devices and supplies (insulin pump, CGM and related 482 supplies) at study closure. Participant may keep the study ketone meter and study glucometer if these 483 devices are not marked for investigational use only. 484 
B28

 
Chapter 5: Testing Procedures and Questionnaires 485 5.1 General Challenge Guidelines 486 All study participants will complete two late bolus meal challenges during each two week treatment 487 period. Participants will be instructed to wait at least 48 hours after switching targets in the treatment 488 period to perform the next set of challenges. 489 A minimum of 48 hours will occur between all challenges for each participant.  490 A paper logbook will be provided to participants that includes a page to record details about each 491 challenge and procedural instructions about how participants will conduct these challenges. This material 492 will be reviewed with each participant, and will be used for source verification for the eCRF database. 493 Before starting each challenge, participants (or parent/guardian if the participant is < 18 years of age) 494 must assure the participant has a working CGM and Control-IQ is active. For pediatric participants, the 495 participant’s parent or guardian must remain with the child at all times and monitor CGM readings 496 frequently during and through meal completion plus 5 hours (3 hours for participants age 2-5). Snacks 497 and glucagon must be available for use during and after each challenge. 498 Participants will be instructed to communicate with study staff within one day prior to each challenge to 499 review procedures and to have a contact with study staff no more than 1 day after the completion of each 500 challenge. The participant or parent/guardian must have an on-call phone number for the study team prior 501 to initiation of each challenge. 502 Hyperglycemia and Hypoglycemia treatment guidelines (sections 3.1.3 and 3.1.2) remain in effect for the 503 challenges, and will be reviewed with participants prior to each challenge.  504 Site staff will directly contact the participant if they do not receive a follow up contact from participants 505 when 24 hours have passed since the time of completion of the planned challenge. 506 5.1.1 Late Bolus Meal Challenges 507 All challenges will be performed with the last meal of the day (dinner) and participants will be instructed 508 not to snack after dinner on days they are performing meal challenges, unless it is to treat hypoglycemia. 509 Participants will also be instructed not to use sleep activity for at least 5 hours (3 hours for participants 510 age 2-5) once starting the meal challenge. Participants will be reminded to disable sleep activity if it is 511 inadvertently activated during the challenge, and to re-enable it at the end of the challenge. 512 Time zero (start of the challenge) is at the first bite of food for the study meal. 513 During each two week treatment period with Control-IQ technology 2.0 use, the two meal challenges will 514 consist of: 515 • Full bolus for the given carbohydrates and calculated correction, given 45 minutes after 516 starting the meal, based on calculated bolus dose using the bolus calculator (with full amount 517 of carbohydrates entered). 518 • Full bolus for the given carbohydrates and calculated correction, given 45 minutes after 519 starting the meal, based on calculated bolus dose using the bolus calculator (with full amount 520 of carbohydrates entered) AND enabling the late bolus feature to 45 minutes later. 521 For each meal challenge, participants will: 522 1. Be in a fasting state for two hours prior to consuming the last meal of the day, with the last 523 manual insulin bolus more than two hours prior to the meal.   524 B29

 
 2. For participants age 6+, only begin the meal challenge if CGM glucose is between 70 mg/dL and 525 200 mg/dL, and CGM trend arrow is not down.   526 For participants age 2-5, only begin the meal challenge if CGM glucose is between 70 mg/dL and 527 250 mg/dL, and CGM trend arrow is not down.   528 Subjects with hyperglycemia > 200mg/dL will reschedule their challenge for another time. If < 529 70 mg/dL, carbohydrate treatment can be given, after which the meal challenge can continue. 530 3. Pediatric participants age 2-5 should have a meal with at least 20 grams of carbohydrates. 531 Participants age 6-13 should have a meal with at least 35 grams of carbohydrates. All other 532 participants should have at least 50 grams of carbohydrates for the study meal challenges. Each 533 participant should use the same meal for all of their meal challenges in the study. Participants 534 will be encouraged to use the same frozen entrée of their choice for consistency. 535 4. Do their best to complete the meal within 30 minutes of starting to eat. 536 5. Write down the start and end time of eating the meal, as well as the meal content (to include 537 amount of carbohydrate, protein and fat) on the study provided logbook. 538 6. Bolus for the meal 45 minutes after starting to eat, entering the full carbohydrate amount and 539 using the recommended dose from the bolus calculator. For one of the two challenges during a 540 single treatment period, use the bolus calculator but do not change the bolus time. For the other 541 challenge during the same treatment period, use the bolus calculator but change the bolus time to 542 45 minutes late. 543 7. Not give an additional bolus during 5 hours (3 hours for participants age 2-5) after the start of 544 meal challenge (i.e., after start of meal), unless BG is above 300 mg/dL for more than 1 hour, or 545 symptoms of hyperglycemia develop. 546 8. Not take additional carbohydrates during 5 hours (3 hours for participants age 2-5) after the start 547 of meal challenge (i.e., after start of meal), unless BG is < 70 mg/dL, or symptoms of 548 hypoglycemia develop. 549 9. Not exercise for 5 hours (3 hours for participants age 2-5) after the meal challenge begins. 550 10. Make sure sleep activity is not active for the 5 hours (3 hours for participants age 2-5) after the 551 meal challenge begins (start of meal). 552 11. Notify the site within 24 hours after completion of each meal challenge. 553 5.2 Laboratory Testing 554 5.2.1 HbA1c 555 HbA1c measurement will be performed locally at the Screening visit. 556 5.2.2 Urine Pregnancy 557 Urine pregnancy testing performed locally at clinical site for females of child-bearing potential at the 558 screening visit, at the start of study device use (for both device training visits), and anytime pregnancy is 559 suspected. 560 5.2.3 Patient Reported Outcomes 561 The following patient reported outcomes/questionnaires and study specific outcomes will be assessed 562 during the trial as per the study visit schedule. 563 B30

 
INSPIRE Survey 564 The INSPIRE (Insulin Delivery Systems: Perceptions, Ideas, Reflections and Expectations) survey was 565 developed to assess various aspects of a user’s experience regarding automated insulin delivery for both 566 patients and family members. The surveys include various topics important to patients with type 1 567 diabetes and their family members based upon >200 hours of qualitative interviews and focus groups. The 568 adult survey includes 31 items; the adolescent survey includes 28 items; and the parent survey includes 30 569 items. Response options for all surveys include a 5-point Likert scale from strongly agree to strongly 570 disagree, along with an N/A option. 571 Administration time is approximately 5 minutes. 572 System Usability Scale (SUS) 573 The System Usability Scale (SUS) is a 10-item questionnaire that measures the overall usability of a 574 system. It is a valid and reliable measure of the perceived usability of a system and is technology-575 agnostic. The questionnaire presents statements with five response options (anchoring the options from 576 strongly disagree to strongly agree) and asks users to rate their agreement to the statements. User scores 577 are transformed into a composite score, from 0 to 100, and this score is taken as an overall measure of the 578 system’s usability; higher scores indicate better perceived usability. 579 Administration time is approximately 5 minutes. 580 Study Specific Questionnaire 581 A study-specific questionnaire will be used to assess experiences and views around the different target 582 ranges, late bolus challenges, freedom to eat and adjust meals, and general thoughts about the trial.  583 Administration time is approximately 5 minutes. 584 
B31

 
Chapter 6: Unanticipated Problem, Adverse Event, and 585 Device Issue Reporting 586 6.1 Unanticipated Problems 587 Site investigators will promptly report to the Coordinating Center and Sponsor on an eCRF all 588 unanticipated problems meeting the criteria below. For this protocol, an unanticipated problem is an 589 incident, experience, or outcome that meets all of the following criteria: 590 • Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are 591 described in the protocol related documents, such as the IRB-approved research protocol and 592 informed consent document; and (b) the characteristics of the subject population being studied 593 • Related or possibly related to participation in the research (possibly related means there is a 594 reasonable possibility that the incident, experience, or outcome may have been caused by the 595 procedures involved in the research) 596 • Suggests that the research places participants or others at a greater risk of harm than was previously 597 known or recognized (including physical, psychological, economic, or social harm) 598 The Coordinating Center will report to the IRB all unanticipated problems not directly involving a 599 specific site such as unanticipated problems that occur at another participating entity such as a pharmacy 600 or laboratory. These instances must be reported to the study IRB within seven calendar days of 601 recognition. The Sponsor will report to the appropriate regulatory authorities if the IRB determines that 602 the event indeed meets the criteria of an Unanticipated Problem requiring additional reporting. 603 6.2 Adverse Events 604 6.2.1 Definitions 605 Adverse Event (AE): Any untoward medical occurrence (including laboratory findings) associated with 606 study procedures, the use of a device, biologic in a study participant, including any comparator used, 607 irrespective of the relationship between the adverse event and the device(s) under investigation (referred 608 to as Adverse Reaction when caused by a drug). 609 Serious Adverse Event (SAE): Any untoward medical occurrence that meets at least one of the following: 610 • Results in death. 611 • Is life-threatening; (a non-life-threatening event which, had it been more severe, might have become 612 life-threatening, is not necessarily considered a serious adverse event). 613 • Requires inpatient hospitalization or prolongation of existing hospitalization. 614 • Results in persistent or significant disability/incapacity or substantial disruption of the ability 615 to conduct normal life functions (sight threatening). 616 • Is a congenital anomaly or birth defect. 617 • Is considered a significant medical event by the investigator based on medical judgment (e.g., may 618 jeopardize the participant or may require medical/surgical intervention to prevent one of the outcomes 619 listed above). 620 Unanticipated Adverse Device Effect (UADE): Any serious adverse effect on health or safety or any 621 life -threatening problem or death caused by, or associated with, a device, if that effect, problem, or death 622 was not previously identified in nature, severity, or degree of incidence in the investigational plan or 623 B32

 
application (including a supplementary plan or application), or any other unanticipated serious problem 624 associated with a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)). 625 Adverse Device Effect (ADE): Any untoward medical occurrence in a study participant which the device 626 may have caused or to which the device may have contributed (Note that an Adverse Event Form is to be 627 completed in addition to a Device Issues Form, unless excluded from reporting as defined in section 628 6.2.2). 629 Comparator: Medical device, therapy (e.g. active treatment, normal clinical practice), placebo or no 630 treatment, used in the control group in a clinical investigation. (ISO 14155:2020) 631 Device Complaints and Malfunctions: A device malfunction or complaint is something that happens 632 to a device or related to device performance, whereas an adverse event happens to a participant. A device 633 complaint may occur independently from an AE, or along with an AE. An AE may occur without a 634 device complaint or there may be an AE related to a device complaint. A device malfunction is any 635 failure of a device to meet its performance specifications or otherwise perform as intended. 636 Performance specifications include all claims made in the labeling for the device. The intended 637 performance of a device refers to the intended use for which the device is labeled or marketed. 638 (21 CFR 803.3). Note: for reporting purposes, sites will not be asked to distinguish between device 639 complaints and malfunctions. 640 Use Error: User action or lack of user action while using the medical device (3.34) that leads to a 641 different result than that intended by the manufacturer or expected by the user. Includes the inability of 642 the user to complete a task. Use errors can result from a mismatch between the characteristics of the user, 643 user interface, task or use environment. Users might be aware or unaware that a use error has occurred. 644 An unexpected physiological response of the patient is not by itself considered a use error. A malfunction 645 of a medical device that causes an unexpected result is not considered a use error. (ISO 14155:2020) 646 6.2.2 Reportable Adverse Events 647 A reportable adverse event includes all events meeting the definition of an adverse event, except for the 648 following: 649 • Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 650 events unless associated with an Adverse Device Effect or discontinuation of the study device.  651 • Skin reactions from sensor or pump infusion set placement are only reportable if severe and/or 652 required treatment. 653 
B33

 
All reportable AEs—whether volunteered by the participant, discovered by study personnel during 654 questioning, or detected through physical examination, laboratory test, or other means—will be reported 655 on an AE form online. Each AE form is reviewed by the Medical Monitor to assess safety and to verify 656 the coding and the reporting that is required. 657 6.2.3 Hypoglycemic Events 658 Hypoglycemia is only reportable as an adverse event when one of the following criteria is met: 659 • a hypoglycemic event occurred meeting the following definition of severe hypoglycemia: the event 660 required assistance of another person due to altered consciousness, and required another person to 661 actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the 662 participant was impaired cognitively to the point that he/she was unable to treat himself/herself, was 663 unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced 664 seizure or loss of consciousness. These episodes may be associated with sufficient neuroglycopenia to 665 induce seizure or loss of consciousness. If glucose measurements are not available during such an 666 event, neurological recovery attributable to the restoration of glucose to normal is considered 667 sufficient evidence that the event was induced by a low glucose concentration. 668 • evaluation or treatment was obtained at a health care provider facility for an acute event involving 669 hypoglycemia, or the participant contacted the site and received guidance following the occurrence of 670 an acute event involving hypoglycemia 671 When a severe hypoglycemia event occurs (as defined above), an Adverse Event Form should be 672 completed. Severe hypoglycemia events should be considered to be serious adverse events with respect to 673 reporting requirements. When a severe hypoglycemia event occurs during use of a study device, it 674 generally will be considered to be unrelated to the device (per section 6.2.5) if the device functioned as 675 intended and there does not appear to be a flaw in how the device is intended to function. 676 6.2.4 Hyperglycemic/Ketotic Events 677 Hyperglycemia is only reportable as an adverse event when one of the following criteria is met:   678 • the event involved DKA, as defined by the Diabetes Control and Complications Trial (DCCT) and 679 described below 680 • evaluation or treatment was obtained at a health care provider facility for an acute event involving 681 hyperglycemia or ketosis, or the participant contacted the site and received guidance on how to 682 manage the hyperglycemia/ketosis 683 • blood ketone level ≥1.0 mmol/L, even if there was no communication with a health care provider at 684 the time of the event 685 Hyperglycemic events are classified as DKA if all of the following are present, or judged likely to have 686 been present based on available data: 687 • Symptoms such as polyuria, polydipsia, nausea, or vomiting; 688 • Serum ketones >1.5 mmol/L or large/moderate urine ketones; 689 • Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO2) <15; and 690 • Treatment provided in a health care facility 691 When a hyperglycemia/ketotic event qualifies as an AE, or as a SAE as defined in section 6.2.1, an 692 Adverse Event Form should be completed. Events meeting DKA criteria should be considered to be 693 serious adverse events with respect to reporting requirements. Hyperglycemia events not meeting criteria 694 B34

 
 for DKA generally will not be considered as serious adverse events unless one of the SAE criteria in 695 section 6.2.1 is met. 696 When a hyperglycemia/DKA event occurs during use of a study device, it generally will be considered to 697 be unrelated to the device (per section 6.2.5) if the device functioned as intended and there does not 698 appear to be a flaw in how the device is intended to function. 699 6.2.5 Relationship of Adverse Event to Study Investigational Device 700 The study investigator will assess the relationship of any adverse event to the study device or study drug. 701 The Medical Monitor also will make this assessment, which may or may not agree with that of the study 702 investigator. Reporting requirements will be based on the Medical Monitor’s assessment. 703 To ensure consistency of adverse event causality assessments, investigators should apply the following 704 general guidelines when determining whether an adverse event is related to a study device or study drug: 705 Unrelated: The AE is clearly not related to a study drug/device and a likely alternative etiology exists 706 such as an underlying disease, environmental or toxic factors or other therapy. 707 Unlikely Related: The AE does not follow a reasonable temporal sequence during or after use of study 708 drug/device and a more likely alternative etiology exists such as an underlying disease, environmental or 709 toxic factors, or other therapy.  710 Possibly Related: The AE occurred in a reasonable time during or after use of study drug/device; but 711 could be related to another factor such as an underlying disease, environmental or toxic factors, or other 712 therapy; and there is a possible, though weak, scientific basis for establishing a causal association 713 between the AE and the study drug/device. 714 Probably Related: The AE occurred in a reasonable time during or after use of study drug/device; is 715 unlikely to be related to another factor such as an underlying disease, environmental or toxic factors, or 716 other therapy; and there is a plausible, though not strong, scientific basis for establishing a causal 717 association between the AE and the study drug/device.  718 Definitely Related: The AE occurred in a reasonable time during or after use of study drug/device; 719 cannot be explained by another factor such as an underlying disease, environmental or toxic factors, or 720 therapy; and there is a strong scientific basis for establishing a causal association between the AE and the 721 study drug/device.  722 Events determined to be Possibly Related, Probably Related, or Definitely Related will be considered 723 ‘Related’ with respect to any required IRB and FDA reporting. 724 6.2.6 Severity (Intensity) of Adverse Events 725 The severity (intensity) of an adverse event will be rated on a three-point scale: (1) mild, (2) moderate, 726 or (3) severe. A severity assessment is a clinical determination of the intensity of an event. Thus, a severe 727 adverse event is not necessarily serious. For example, itching for several days may be rated as severe, but 728 may not be clinically serious. 729 MILD: Usually transient, requires no special treatment, and does not interfere with the participant’s daily 730 activities. 731 MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the participant 732 and may interfere with daily activities, but is usually ameliorated by simple therapeutic measures and 733 participant is able to continue in study. 734 SEVERE: Interrupts a participant’s usual daily activities, causes severe discomfort, may cause 735 discontinuation of study device, and generally requires systemic drug therapy or other treatment. 736 B35

 
 6.2.7 Expectedness 737 For a serious adverse event that is considered possibly related to study device, the Medical Monitor will 738 classify the event as unexpected if the nature, severity, or frequency of the event is not consistent with the 739 risk information previously described in the protocol, labeling, or Investigator Brochure. 740 6.2.8 Coding of Adverse Events 741 Adverse events will be coded using the MedDRA dictionary. 742 6.2.9 Outcome of Adverse Events 743 The outcome of each reportable adverse event will be classified by the investigator as follows: 744 • RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae. Record 745 the AE/SAE stop date. 746 • RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized without 747 change in the event anticipated. Record the AE/SAE stop date. 748 • FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that was the 749 cause of death should be reported as fatal. AEs/SAEs that were ongoing at the time of death; 750 however, were not the cause of death, will be recorded as “resolved” at the time of death. 751 • NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the event 752 was ongoing with an undetermined outcome. 753 An ongoing outcome will require follow-up by the site in order to determine the final outcome 754 of the AE/SAE. The outcome of an ongoing event at the time of death that was not the cause of 755 death, will be updated and recorded as “resolved” with the date of death recorded as the stop 756 date. 757 • UNKNOWN – An unknown outcome is defined as an inability to access the participant or the 758 participant’s records to determine the outcome (for example, a participant that was lost to follow-up). 759 If any reported adverse events are ongoing when a participant completes the study (or withdraws), 760 adverse events classified as UADEs or related SAEs or SUSARs will be followed until they are either 761 resolved, or have no prospect of improvement or change, even after the participant has completed all 762 applicable study visits/contacts. For all other adverse events, data collection will end at the time the 763 participant completes the study. Note: participants should continue to receive appropriate medical care 764 for an adverse event after their participation in the study ends. 765 6.3 Reportable Device Issues 766 All UADEs and ADEs as defined in section 6.2.1 will be reported as both ‘device issues’ and adverse 767 events, except for skin reactions from CGM sensor placement or pump infusion set placement that do not 768 require pharmacologic treatment. 769 Device issues will be reported except in the following circumstances. These occurrences are expected and 770 will not be reported on a Device Issue Form assuming criteria for a UADE or ADE have not been met: 771 • CGM sensor lasting fewer days than expected per manufacturer 772 • CGM tape adherence issues 773 • Pump infusion set insertion lasting fewer days than expected per manufacturer 774 • Battery lifespan deficiency due to inadequate charging or extensive wireless communication 775 B36

 
• Intermittent device component disconnections/communication failures not requiring system 776 replacement or workaround/resolution not specified in user guide/manual. 777 • Device issues clearly addressed in the user guide manual that do not require additional 778 troubleshooting 779 6.4 Timing of Event Reporting 780 SAEs possibly related to a study device, study drug, or study participation and UADEs must be reported 781 by the site to the Sponsor within 1 working day of the site becoming aware of the event. This can occur 782 via phone or email, or by completion of the appropriate eCRFs as applicable. If the form(s) are not 783 initially completed, they should be competed as soon as possible after there is sufficient information to 784 evaluate the event. All other reportable ADEs and other reportable AEs should be submitted by 785 completion on the eCRF(s) within 7 days of the site becoming aware of the event.  786 The Sponsor will notify all participating investigators of any adverse event that is serious, related, and 787 unexpected. Notification will be made within 10 working days after the Sponsor becomes aware of the 788 event. 789 Each principal investigator is responsible for reporting serious study-related adverse events and abiding 790 by any other reporting requirements specific to his/her Institutional Review Board or Ethics Committee.  791 Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a UADE has 792 occurred, and if indicated, report the results of the investigation to all overseeing IRBs, and the FDA 793 within 10 working days of the Sponsor becoming aware of the UADE per 21CFR 812.46(b). The Sponsor 794 must determine if the UADE presents an unreasonable risk to participants. If so, the Sponsor must ensure 795 that all investigations, or parts of investigations presenting that risk, are terminated as soon as possible but 796 no later than 5 working days after the Sponsor makes this determination and no later than 15 working 797 days after first receipt notice of the UADE. 798 The investigators are also required to report, without unjustified delay, all device complaints and 799 malfunctions that could have led to a UADE, including device complaints and malfunctions, irrespective 800 of whether an adverse event occurred. 801 6.5 Safety Oversight 802 The study Sponsor’s Medical Director will serve as Medical Monitor, and will review all reported adverse 803 events, including all cases of severe hypoglycemia and DKA, and adverse device effects that are reported 804 during the study. SAEs typically will be reviewed within 1 working day of reporting. Other AEs typically 805 will be reviewed on a weekly basis.  806 The Medical Monitor will determine if the events require expedited reporting to FDA, IRB and/or all 807 participating sites. In addition, the Medical Monitor will confirm the MedDRA code assigned and 808 adjudicate events as specified in the safety management plan for relatedness to the study procedure and 809 investigational device, assess seriousness and severity, and determine if the event the event is anticipated 810 or unanticipated. Both the investigator’s and Medical Monitor’s assessments will be recorded, however, 811 the adjudication decision of the Medical Monitor will be used for the final classification of events, 812 including relatedness to the study procedures and/or the investigational device, for the determination of 813 safety endpoints and for all regulatory reports, product labeling, and publications or presentations. 814 
B37

 
 6.6 Stopping Criteria 815 6.6.1 Participant Discontinuation of Study Device 816 In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA event 817 (or a malfunction that could have led to severe hypoglycemia or DKA), use of the study device will be 818 suspended for that participant while the problem is diagnosed. The UADE will be reported to the IRB and 819 FDA. After assessment of the problem and any correction, use of the study device will not be restarted 820 until approval is received from the IRB and FDA. 821 In the absence of a device malfunction, use of the study device by a participant will be discontinued if 822 any of the following occur:  823 • The investigator believes it is unsafe for the participant to continue on the intervention. This could be 824 due to the development of a new medical condition or worsening of an existing condition; or 825 participant behavior contrary to the indications for use of the device that imposes on the participant’s 826 safety 827 • The participant requests that the treatment be stopped 828 • Participant pregnancy 829 • One distinct episodes of DKA in the study treatment period as defined in section 6.2.4 830 • One distinct severe hypoglycemia events in the study treatment period as defined in section 6.2.3 831 Each DKA or severe hypoglycemia event will be reviewed by the Medical Monitor with respect to 832 determination of cause and whether the occurrence of the event can be attributed to use of the study 833 device or study drug.  834 6.6.2 Criteria for Suspending or Stopping Overall Study 835 In addition to the suspension of device use due to a UADE as described in section 6.6.1, study activities 836 could be similarly suspended if the manufacturer of any constituent study device requires stoppage of 837 device use for safety reasons (e.g. product recall). The affected study activities may resume if the 838 underlying problem can be corrected by a protocol or system modification that will not invalidate the 839 results obtained prior to suspension. 840 Closed-loop system use will also be suspended if there are five or more cases of severe hypoglycemia or 841 five or more cases of DKA across the entire study in participants who have initiated Control-IQ 842 technology 2.0 use. The IRBs and FDA will be notified. After assessment of the problem and any 843 corrections are implemented, use of the closed-loop system may be restarted if approval is received from 844 the IRBs and FDA. 845  846 
B38

 
Chapter 7: Miscellaneous Considerations 847 7.1 Drugs Used as Part of the Protocol 848 Subjects will use their own Humalog (insulin lispro) or Novolog (insulin aspart) during the Run In and 849 Treatment Period with the study devices. 850 7.2 Collection of Medical Conditions and Medications 851 Pre-Existing Conditions: Any medical condition that is either present at screening, a chronic disease, 852 or a prior condition that could impact the participant’s health during the course of the study (e.g., prior 853 myocardial infarction or stroke) will be recorded. 854 Medical Conditions Developing During the Study: Medical conditions developing during the study will 855 be reviewed by the investigator for their relationship to the study device. 856 Medications: All medications in use at the time of screening or added during the course of the study will 857 be recorded. Nutraceuticals and preventative treatment also will be recorded. Medications only taken as 858 needed either can be recorded when prescribed or only recorded if used during the study. Glucagon for 859 treatment of severe hypoglycemia will only be recorded if used during the study. 860 7.3 Prohibited Medications, Devices, Treatments, and Procedures 861 Treatment with any insulin other than Humalog or Novolog insulin with the study pumps is not permitted. 862 Treatment with a non-insulin glucose -lowering agent, other than metformin, is not permitted, including 863 GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas. 864 The investigational study devices (t:slim X2 insulin pump with Control-IQ technology 1.5 or 2.0) and 865 study sensor and transmitter (Dexcom CGM sensor and transmitter) must be removed before magnetic 866 resonance imaging (MRI), computed tomography (CT) or diathermy treatment. Participants may continue 867 in the trial after temporarily discontinuing use if requiring one of the above. 868 7.4 Rescue Medications, Treatments, and Procedures 869 Each participant will be required to have a glucagon preparation for rescue therapy for severe 870 hypoglycemia. 871 7.5 Pregnancy Reporting 872 If pregnancy occurs, the participant will be discontinued from the study. The occurrence of pregnancy 873 will be reported to the Coordinating Center within seven days and to the IRB as an Unanticipated 874 Problem within seven calendar days. 875 7.6 Participant Compensation 876 Participant compensation will be specified in the informed consent form. 877 7.7 Participant Withdrawal 878 Participation in the study is voluntary, and a participant may withdraw at any time. For participants who 879 withdraw, their data will be used up until the time of withdrawal. 880  881 
B39

 
 Chapter 8: Statistical Considerations 882 8.1 General Statistical Considerations 883 Summary statistics will be generated for all relevant variables. In the comparison of continuous variables, 884 distributions will be tested for the normality assumption. If standard parametric techniques are found to be 885 inadequate, an appropriate non-parametric technique will be used. Categorical variables will be presented 886 using frequencies and percentages and compared using differences in proportions unless stated otherwise. 887 For safety/adverse event reporting, both the number of overall events and the number of subjects 888 experiencing that event will be tabulated. No corrections will be made for multiple testing procedures. All 889 analyses will be conducted using SAS® version 9.4 or higher. Although this study features a crossover 890 design, it will be assumed for the exploratory purposes of this analysis that there are no residual period 891 effects and no carryover effects present. The correlated nature of data collected by the same subject across 892 multiple conditions will be accounted for in the statistical modeling, such as using a paired t-test for 893 comparing continuous outcomes. 894 8.2 Statistical Hypotheses 895 The primary objective of the study is assessment of safety. Therefore, there are no formal statistical 896 hypotheses associated with any of the endpoints. Safety endpoints for SH and DKA will be compared to 897 historical published data. Efficacy endpoints will be compared across study periods with the run-in period 898 designated as the comparator study period. P-values for differences between study periods on both safety 899 and efficacy endpoints will be calculated, however, will not be used for formal statistical inference due to 900 the exploratory nature of the study objectives and the lack of correction for multiple testing. 901 8.3 Sample Size 902 The sample size of at least 30 adults and adolescents age 14+ years old, 30 children age  6-13 years old, 903 and 12 preschool participants age 2-5 years of age who will complete the trial was selected to have a 904 reasonable time period of use in each age cohort to establish safety, with each subject completing 2 weeks 905 of Control-IQ 1.5 technology use, 2 weeks of Control-IQ 2.0 technology use with the target of 112.5 to 906 160 mg/dL, and 2 weeks of Control-IQ 2.0 technology use with the target of 90-130 mg/dL. The choice of 907 sample size is not based on statistical principles. In addition, the sample size assures a reasonable number 908 of late bolus meal challenges completed.  909 There is a further enrollment goal of at least half of all participants in each age group have an HbA1c at 910 baseline of ≥ 7.5%, and have at least 6 participants age 14-17. 911 8.4 Outcome Measures 912 Primary Endpoints 913 1. Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed 914 for treatment) during study compared with data on severe hypoglycemic events reported by T1D 915 Exchange clinic registry over a 3-month time period 916 2. Diabetic ketoacidosis during study compared with data on DKA events  917 3. Number of unanticipated adverse device effects 918 4. Number of other serious device-related adverse events 919 Secondary Endpoints  920 1. All device-related adverse events 921 B40

 
 2. CGM hypoglycemia outcomes, compared between the three study time periods 922 a. Overall % time <54 mg/dL 923 b. Overall % time <70 mg/dL 924 3. Times in ranges-overall (70-180 mg/dL, >180 mg/dL, >250 mg/dL, 70-140 mg/dL) compared 925 between the three study time periods 926 4. Mean glucose compared between the three study time periods. 927 5. Overall variability (CV and SD) compared between the three study time periods 928 6. Secondary endpoints 2 - 5 compared during daytime and nighttime, across the three study time 929 periods 930 7. Secondary endpoints 2 - 5 as well as adverse events, during the study meal challenge periods, for 931 late bolus feature use compared to normal bolus in the meal challenges. 932 8. Time to intervention for hypo- or hyperglycemia during the study meal challenge periods, for late 933 bolus feature use compared to normal bolus in the meal challenges. 934 9. Number of interventions for hypo- or hyperglycemia during the study meal challenge periods for 935 late bolus feature use compared to normal bolus in the meal challenges. 936 10. Subgroup Analysis for all metrics by age cohort, baseline HbA1c cohort (HbA1c at baseline of ≥ 937 7.5%, yes/no), and target activity use (standard target, lower target, sleep activity, exercise 938 activity). 939  940 8.5 Analysis Datasets  941 Safety analysis set: All participants who initiate the Treatment Period and use the study device at least 942 one time (including training).  943 CGM analysis set: Any member of the Safety Analysis Set who has at least 24 hours of CGM data during 944 either Treatment Period. CGM data occurring within the meal challenge windows (from time of start of 945 meal up to 5 hours afterwards [3 hours for age 2-5]) will not be used to determine whether a subject is 946 included in CGM analysis set or not. 947 Late bolus meal challenge set: Any member of the Safety Analysis Set who has at least 24 hours of CGM 948 data during the Treatment Period, and who has at least 3 hours of CGM data for at least one meal 949 challenge. 950 8.6 Analysis of Endpoints 951 8.6.1 Analysis of the Safety Event Endpoints 952 Safety events (not including CGM defined events defined in sections 6.2.2, 6.2.3, and 6.2.4) will be based 953 on Safety analysis set, and tabulated for each primary endpoint as the number of events per participant, 954 the number of participants with ≥ 1 event, and the rate of events per 100 person-years. A 95% confidence 955 interval will be calculated for the rate of events per 100 person-years. 956 Since study eligibility excluded participants with 2 or more severe hypoglycemia or DKA events in the 957 prior 6 months, an unbiased comparison of the event rate during the Treatment Period with the pre-study 958 event rate is not possible. Therefore, the severe hypoglycemia and DKA event rates will be compared 959 with the T1D Exchange data,4 which reported the frequency of 1 or more severe hypoglycemia and DKA 960 events in the prior 3 months. The proportion of participants with events during the Treatment Period (each 961 B41

 
period separately) will be compared with the run-in period as well as with the T1D Exchange frequency. 962 Differences in proportions across the three study periods (two active treatments and the run in) will be 963 estimated in a pairwise fashion, and statistical significance will be assessed using a normal approximation 964 to a binomial distribution. 965 8.6.2 Analysis of Other Safety Endpoints 966 Safety summaries will be based on Safety analysis set. All adverse events reported over the course of the 967 study will be summarized by study period for run-in and both treatment periods separately and overall. 968 Adverse events will be tabulated by System Organ Class and Preferred Term based on MedDRA version 969 22.0. Adverse events will also be summarized by seriousness, severity, and relationship to study 970 procedures and the investigational device. Except where indicated, a subject reporting the same adverse 971 event more than once will be counted once when calculating the number and percent of subjects with that 972 particular event. 973 Adverse events leading to death or to discontinuation from the study will be listed separately. A listing of 974 all adverse events will be provided. 975 8.6.3 Analysis of CGM Endpoints 976 CGM metrics will be assessed in CGM analysis set, and computed for the Run-In and both Treatment 977 Periods separately. CGM metrics will be computed per subject over 24 hours, during daytime (6am-978 11:59pm), and during nighttime (12am-5:59am), as well as by age cohort (adults/adolescents, children 6 – 979 13, and preschool), baseline HbA1c cohort (HbA1c at baseline of ≥ 7.5%,yes/no), and target activity use 980 as specified by the device (standard target, lower target, sleep activity, and exercise activity). 981 The main statistical comparison will be made between the three 2-week periods (Run In, Treatment 982 Period at standard target, Treatment Period at lower target). The comparison will be pairwise – Run-in vs 983 standard targe, Ru-in vs lower target, and standard vs lower target. The percent time in glycemic ranges 984 will be calculated as the number of measurements in the specified range divided by the total number of 985 measurements for which it can be determined whether or not the measurement was in specified range. 986 The “Low” and “High” CGM readings will be included in all analyses. Percent time will be compared 987 using a paired t-test assuming sufficient normality assumptions hold, otherwise an appropriate non-988 parametric method will be utilized.  989 8.6.4 Analysis of Late Bolus Meal Challenges 990 All analyses in section 8.6.4 will be conducted in the late bolus meal challenge analysis set. Data included 991 in these analyses will be restricted to data during the meal challenge window (start of meal through 5 992 hours from meal imitation [3 hours for age 2-5]). The subgroups assessed will be the same as sections 993 8.6.1 – 8.6.3 (age cohort, baseline HbA1c cohort (HbA1c at baseline of ≥ 7.5%. yes/no), etc.) 994 8.6.4.1 Late Bolus Meal Challenge Safety and CGM Subgroup Analysis 995 Two challenges are expected per subjects per treatment period for a total of four challenges, therefore 996 agreement of outcomes will need to be assessed. For continuous outcomes, two sets of Pearson’s 997 correlation coefficients will be calculated to measure concordance: one restricted to each treatment period 998 (higher range target and lower range target), and a single coefficient for all four challenges. For 999 categorical outcomes, a Cohen’s kappa statistic for agreement or a similarly appropriate statistic will be 1000 calculated and presented to describe agreement/dependence of outcomes by individual subjects. Results 1001 will be compared by treatment period and across treatment periods. 1002 The analyses described in sections 8.6.1, 8.6.2, and 8.6.3 will be repeated for subjects included in the late 1003 bolus meal challenge set. For the CGM outcomes, the mean of the CGM metrics for the two late meal 1004 B42

 
bolus challenges within study period will be used to account for within-subject non-independence (i.e. 1005 one data value per subject per study period).  1006 8.6.4.2  Time to Intervention Analysis 1007 Time to intervention for both hypo- or hyperglycemia during the study meal challenge periods will be 1008 summarized. Time to intervention is defined as the time (in minutes) from start of meal until the first 1009 treatment is given as defined in Section 6.2. If multiple interventions are needed to treat hypo- or 1010 hyperglycemia during the meal challenge, only time to the earliest intervention will be summarized. The 1011 results will be presented using general summary statistics, as well as utilizing Kaplan-Meier time-to-event 1012 analysis where subjects who complete the meal challenge without requiring any intervention will be right-1013 censored. A cox proportional hazards model will be fit comparing time to intervention between the two 1014 active treatment periods. A p-value from the log-rank test will be used to evaluate whether there is 1015 evidence of a difference between the two target ranges with respect to time to intervention. Results will be 1016 compared by treatment period and across treatment periods. 1017 8.6.4.3 Number of interventions analysis 1018 Number of interventions for hypo- or hyperglycemia during the study meal challenge periods will be 1019 summarized both overall and by type. The results will be presented using general summary statistics. 1020 Type of intervention may include timing of intervention (during meal, less than one hour after starting 1021 meal, greater than one hour after meal start), the number of carbs administered (grouped in increments of 1022 10 grams), and the timing of carb administration (less than 15 minutes per administration vs 15 minutes 1023 or more). The categories and groupings utilized for intervention type will be expanded or decreased based 1024 on the types of interventions that actually occur in the study. Results will be compared by treatment 1025 period and across treatment periods. 1026 Type of intervention will be reviewed and assessed by the study Medical Monitor prior to analysis to 1027 define the logic that can be applied across all subjects (e.g., an intervention that occurred more than 15 1028 minutes after the previous intervention will count as new intervention). Different logic may be applied to 1029 different age cohorts. This logic will be fully detailed in the final clinical study report.  1030 8.7 Intervention Adherence 1031 The following tabulations will be performed: 1032 • Sensor use – percent time of use as a function of overall treatment period 1033 • Sensor use is defined as percent of time CGM is recorded as active (to include warmup) vs total 1034 study time. 1035 • Closed loop system use – percent time of use as a function of overall treatment period 1036 • Closed loop system use is defined as percent of time closed-loop is recorded as active (to include 1037 pinning in sensor warmup) vs total study time. 1038 • Percent time in different operational modes as a function of overall treatment period 1039 • The investigational device allows for the following operational modes: standard target, lower 1040 target, sleep activity, and exercise activity. 1041 For intervention adherence, overall treatment period is calculated from the start of the treatment period to 1042 the end of the treatment period where any gaps in CGM data are ignored.  1043 
B43

 
1 8.8 Protocol Adherence and Retention 1044 The following tabulations and analyses will be performed to assess protocol adherence for the study: 1045 • Number of protocol deviations by site and by type, and number of unique subjects with each type of 1046 protocol deviation  1047 • Disposition summary (e.g., chart, table) accounting for all enrolled participants at each scheduled visit 1048 • Number of and reasons for unscheduled visits and phone calls 1049 • Number of participants who were enrolled but did not enter the Treatment Period and reasons 1050 • Number of participants who stopped treatment and reasons 1051 8.9 Baseline Descriptive Statistics 1052 Baseline demographic and clinical characteristics of the cohort of participants who initiate the Treatment 1053 Period will be summarized in a table using summary statistics appropriate to the distribution of each 1054 variable. Descriptive statistics will be displayed by treatment group for the following: 1055 • Age 1056 • Sex 1057 • Race 1058 • Ethnicity 1059 • Socio-economic factors (income, education, and/or insurance status) 1060 • Diabetes duration 1061 • HbA1c 1062 • BMI 1063 • Total daily insulin 1064 • Prior severe hypoglycemia and DKA events in the last 6 months 1065 8.10 Additional Tabulations and Analyses 1066 The following data will be tabulated at baseline, for the run-in period, and for the two treatment periods. 1067 • Insulin metrics (units/kg): total daily insulin, total daily basal insulin, total daily bolus insulin (plus 1068 total daily manual bolus, total daily automated bolus) 1069 8.11 Device Issues 1070 The following tabulations will be performed with respect to device issues: 1071 • Number of device issues by type, and number of unique subjects with each type of device issue 1072 8.12 Planned Interim Analyses 1073 No formal interim analyses are planned. 1074 
B44

 
1 8.13 Subgroup Analyses 1075 Results will be tabulated according to age cohort, baseline HbA1c category, and target activity use 1076 (standard target, lower target, sleep activity, exercise activity). There is an enrollment goal of at least half 1077 of all participants in each age group have an HbA1c at baseline of ≥ 7.5%, and all participants meeting 1078 that criteria will be analyzed as a subgroup. 1079 8.14 Multiple Comparison/Multiplicity 1080 There are no adjustments performed for multiple comparisons.  1081 8.15 Handling of Missing Data 1082 All practical monitoring and follow-up steps will be taken to ensure complete and accurate data 1083 collection. All analyses will be based on available data only; no imputation for missing data is planned.  1084 8.16 General Statistical Considerations 1085 Up to six sites in the US will enroll subjects into the study. For the purposes of statistical analyses and   1086 data summaries, data from all study centers will be pooled. Not official assessment of poolability will be 1087 performed.  1088 Unless otherwise specified, continuous variables will be summarizing using count, mean, median, 1089 standard deviation, and range. 95% confidence intervals, and/or first and third quartile may be presented 1090 were appropriate. Categorical variables will be summarized using count and percent of each level of 1091 categorical variable. Any statistical testing will be performed at a two-sided significance level of 5% with 1092 no adjustment for multiple testing. If the observed data are found not to follow a normal distribution, non-1093 parametric methods may be employed (such as Wilcoxon rank sum test as appropriate).  1094 The statistical software package SAS® 9.3 or later will be used for all data derivations, summaries, 1095 listings, and statistical analyses. Additional statistical software may be used for graphics or validation 1096 purposes as appropriate.1097 
B45

 
Chapter 9: Data Collection and Monitoring 1098 9.1 Case Report Forms and Other Data Collection 1099 The main study data are collected on electronic case report forms (eCRFs). When data are directly 1100 collected in electronic case report forms, this will be considered the source data. For any data points 1101 for which the eCRF is not considered source (e.g. lab results that are transcribed from a printed report 1102 into the eCRF, data collected in the electronic medical record, study specific source worksheets, etc.), the 1103 original source documentation will be maintained in the participant’s study chart or medical record. This 1104 source must be readily verifiable against the values entered into eCRF.  1105 Electronic device data files are obtained from the study software and individual hardware components. 1106 These electronic device files are considered the primary source documentation. 1107 9.2 Study Records Retention 1108 Each participating site will maintain appropriate medical and research records for this trial, in 1109 compliance with GCP and regulatory and institutional requirements for the protection of confidentiality of 1110 participants. 1111 Study documents should be retained for a minimum of 2 years after the last approval of a marketing 1112 application in an ICH region and until there are no pending or contemplated marketing applications in an 1113 ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development 1114 of the investigational product. These documents should be retained for a longer period, however, 1115 if required by local regulations. No records will be destroyed without the written consent of the sponsor, 1116 if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 1117 longer need to be retained. 1118 9.3 Quality Assurance and Monitoring 1119 Designated personnel from the Coordinating Center will be responsible for maintaining quality 1120 assurance (QA) and QC systems to ensure that the clinical portion of the trial is conducted and data are 1121 generated, documented and reported in compliance with the protocol, GCP and the applicable regulatory 1122 requirements, as well as to ensure that the rights and wellbeing of trial participants are protected and that 1123 the reported trial data are accurate, complete, and verifiable. Adverse events will be prioritized for 1124 monitoring. 1125 A monitoring plan will be developed and revised as needed during the course of the study. Study conduct 1126 and monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan will describe in 1127 detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail 1128 monitoring will be performed, and the distribution of monitoring reports. 1129 The data of most importance for monitoring at the site are participant eligibility and adverse events. 1130 Therefore, the monitoring plan will focus on these areas. As much as possible, remote monitoring will be 1131 performed in real-time with on-site monitoring performed to evaluate the verity and completeness of 1132 the key site data. Elements of the monitoring may include: 1133 
B46

 
• Qualification assessment, training, and certification for sites and site personnel 1134 • Oversight of Institutional Review Board (IRB) coverage and informed consent procedures 1135 • Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol review of 1136 entered data and edits, statistical monitoring, study closeout 1137 • On-site monitoring (site visits): source data verification, site visit report 1138 • Agent/Device accountability 1139 • Communications with site staff 1140 • Patient retention and visit completion 1141 • Quality control reports 1142 • Management of noncompliance 1143 • Documenting monitoring activities 1144 • Adverse event reporting and monitoring 1145 Coordinating Center representatives or their designees may visit the study facilities at any time in order 1146 to maintain current and personal knowledge of the study through review of the records, comparison 1147 with source documents, observation and discussion of the conduct and progress of the study. 1148 The investigational site will provide direct access to all trial related source data/documents, and reports 1149 for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory 1150 authorities. 1151 9.4 Protocol Deviations 1152 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1153 requirements. The noncompliance may be either on the part of the participant, the investigator, or the 1154 study site staff. A significant (or major) deviation is any deviation that departs from the established 1155 materials in such a way that it poses an increase in the risk to subjects, adversely affects the welfare, 1156 rights, or safety of the research subjects, or negatively influences the scientific study integrity. As a 1157 result of a significant deviation, a corrective and preventive action plan shall be developed by the site 1158 and implemented promptly. 1159 The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details 1160 about the handling of protocol deviations will be included in the monitoring plan. 1161  1162 
B47

 
Chapter 10: Ethics/Protection of Human Participants 1163 10.1 Ethical Standard 1164 The investigator will ensure that this study is conducted in full conformity with Regulations for the 1165 Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR 1166 Part 56, and/or the ICH E6. 1167 10.2 Institutional Review Boards 1168 The protocol, informed consent form(s), recruitment materials, and all participant materials will be 1169 submitted to the IRB for review and approval. Approval of both the protocol and the consent form must 1170 be obtained before any participant is enrolled. Any amendment to the protocol will require review and 1171 approval by the IRB before the changes are implemented to the study. All changes to the consent form 1172 will be IRB approved; a determination will be made regarding whether previously consented participants 1173 need to be re-consented. 1174 10.3 Informed Consent Process 1175 10.3.1 Consent Procedures and Documentation 1176 Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 1177 and continues throughout the individual’s study participation. Extensive discussion of risks and possible 1178 benefits of participation will be provided to the participants and their families. Consent forms will be 1179 IRB-approved and the participant will be asked to read and review the document. The investigator will 1180 explain the research study to the participant and answer any questions that may arise. All participants 1181 will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, 1182 and potential risks of the study and of their rights as research participants. Participants will have the 1183 opportunity to carefully review the written consent form and ask questions prior to signing. 1184 The participants should have the opportunity to discuss the study with their surrogates or think about 1185 it prior to agreeing to participate. The participant will sign the informed consent document prior to any 1186 procedures being done specifically for the study. The participants may withdraw consent at any time 1187 throughout the course of the trial. A copy of the informed consent document will be given to the 1188 participants for their records. The rights and welfare of the participants will be protected by emphasizing 1189 to them that the quality of their medical care will not be adversely affected if they decline to participate 1190 in this study. 1191 10.3.2 Participant and Data Confidentiality 1192 Participant confidentiality is strictly held in trust by the participating investigators, their staff, and the 1193 sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and 1194 genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, 1195 documentation, data, and all other information generated will be held in strict confidence. No information 1196 concerning the study or the data will be released to any unauthorized third party without prior written 1197 approval of the sponsor. 1198 The study monitor, other authorized representatives of the sponsor, representatives of the IRB, regulatory 1199 agencies or company supplying study product may inspect all documents and records required to be 1200 maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) 1201 and pharmacy records for the participants in this study. The clinical study site will permit access to such 1202 records. 1203 
B48

 
The study participant’s contact information will be securely stored at each clinical site for internal use 1204 during the study. At the end of the study, all records will continue to be kept in a secure location for as 1205 long a period as dictated by the reviewing IRB, institutional policies, sponsor requirements, and 1206 applicable regulations. 1207 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 1208 be transmitted to and stored at the Coordinating Center. This will not include the participant’s contact or 1209 identifying information, unless otherwise specified in the informed consent form. Rather, individual 1210 participants and their research data will be identified by a unique study identification number. The study 1211 data entry and study management systems used by clinical sites and by the Coordinating Center research 1212 staff will be secured and password protected. At the end of the study, all study databases will be de-1213 identified and archived at the Coordinating Center. 1214 10.3.3 Future Use of Stored Specimens and Data 1215 Data collected for this study will be analyzed and stored at the Coordinating Center. After the study is 1216 completed, a dataset will be provided to the study Sponsor. 1217 No biologic specimens will be stored. 1218  1219 
B49

 
Chapter 11: References 1220  1221 1. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, 1222 Levy CJ, Pinsker JE, Wadwa RP, Dassau E, Doyle FJ 3rd, Anderson SM, Church MM, 1223 Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW; iDCL 1224 Trial Research Group.  Six-month randomized, multicenter trial of closed-loop control in 1225 type 1 diabetes. N Engl J Med. 2019; 381:1707-1717. 1226 2. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, 1227 Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, 1228 Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial 1229 Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. 1230 N Engl J Med. 2020; 383:836-845. 1231 3. Breton M, Kovatchev B. One year real-world use of the Control-IQ advanced hybrid closed 1232 loop technology. Diabetes Technol Ther. 2021;23:601-608. 1233 4. Foster et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 1234 2016-2018. Diabetes Technol Ther. 2019; 21:66-72. 1235  1236 
B50
